Data availability
The authors confirm that the data supporting the findings of this study are available within the article or its supplementary materials.
References
Kent JR, Almond MK, Dhillon S (2001) Azithromycin: an assessment of its pharmacokinetics and therapeutic potential in CAPD. Perit Dial Int 21(4):372–7
Sugie M, Asakura E, Zhao YL, Torita S, Nadai M, Baba K, Kitaichi K, Takagi K, Takagi K, Hasegawa T (2004) Possible involvement of the drug transporters P glycoprotein and multidrug resistance-associated protein Mrp2 in disposition of azithromycin. Antimicrob Agents Chemother 48(3):809–814
Nguyen TD, Markova S, Liu W, Gow JM, Baldwin RM, Habashian M, Relling MV, Ratain MJ, Kroetz DL (2013) Functional characterization of ABCC2 promoter polymorphisms and allele-specific expression. Pharmacogenomics J 13(5):396–402
Robertson SM, Luo X, Dubey N, Li C, Chavan AB, Gilmartin GS, Higgins M, Mahnke L (2015) Clinical drug-drug interaction assessment of ivacaftor as a potential inhibitor of cytochrome P450 and P-glycoprotein. J Clin Pharmacol 55(1):56–62
Howsare MM, El-Kersh K (2017) Isolated extreme elevation of alkaline phosphatase associated with lumacaftor/ivacaftor therapy: first report. Am J Respir Crit Care Med 195:A1509
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethical statement
The patient’s relatives gave written informed consent for publication of the case report.
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Delmez, Q., Haufroid, V., Gohy, S. et al. Elevation of alkaline phosphatase and long-term drug therapy for cystic fibrosis. Eur J Clin Pharmacol 78, 699–701 (2022). https://doi.org/10.1007/s00228-021-03272-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-021-03272-0